LXRX
Lexicon Pharmaceuticals, Inc.
There isn't enough reported data to score LXRX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
LXRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
LXRX's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LXRX PE Valuation
LXRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
LXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LXRX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.04 |
| Q2 2026 | -$0.15 | +$0.17 |
| Q1 2026 | -$0.07 | +$0.43 |
| Q4 2025 | -$0.14 | +$0.49 |
| Q3 2025 | -$0.18 | +$0.57 |
| Q2 2025 | -$0.32 | +$0.46 |
| Q1 2025 | -$0.50 | +$0.33 |
| Q4 2024 | -$0.63 | +$0.17 |
LXRX is still losing money, but far less than before: $0.14 per share over the past year, against $1.05 at its worst in late 2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over LXRX on earnings quality, reporting a profit while its opponent remains loss making.
LXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | -21% |
| Q2 2026 | $692K | -98% |
| Q1 2026 | $21.1M | +1572% |
| Q4 2025 | $5.5M | -79% |
| Q3 2025 | $14.2M | +710% |
| Q2 2025 | $28.9M | +1653% |
| Q1 2025 | $1.3M | +12% |
| Q4 2024 | $26.6M | +3683% |
LXRX's revenue has slid since its 2025 peak: $11M last quarter, down 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -129% | -43 points |
| Q2 2026 | -3835% | -3848 points |
| Q1 2026 | -4.7% | +2030 points |
| Q4 2025 | -269% | -146 points |
| Q3 2025 | -86% | +3554 points |
| Q2 2025 | 13% | +3374 points |
| Q1 2025 | -2035% | +1977 points |
| Q4 2024 | -123% | +6534 points |
LXRX's operating margin was −129% last quarter, down 43 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over LXRX on profitability, with a higher operating margin.
LXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | +$15.8M |
| Q1 2026 | -$14.7M | +$29M |
| Q4 2025 | -$17.2M | +$4.7M |
| Q3 2025 | -$23.8M | +$30.1M |
| Q1 2025 | -$43.8M | +$11.4M |
| Q4 2024 | -$22M | +$28.6M |
| Q3 2024 | -$53.9M | -$12.2M |
| Q2 2024 | -$48.8M | -$10.5M |
LXRX has burned cash in almost every quarter: −$49M over the past year, against −$144M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over LXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +7.3M shares |
| 1 year | +22% | +81.6M shares |
| 3 years | +82% | +200M shares |
| 5 years | +205% | +299M shares |
| Available history | +319% | +339M shares |
LXRX has 445M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $1.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $824,000 |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over LXRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
LXRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -1.8x | Net Cash |
| Q1 2020 | 1.9x | Healthy |
| Q4 2019 | 1.4x | Healthy |
LXRX has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 27.1 | Neutral |
LXRX's weekly RSI is 48 (neutral) and its Stochastic is 27 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
LXRX PE vs Healthcare Sector
| Metric | LXRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LXRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
LXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.66 | 9.6% above |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $1.79 | 1.7% above |
| 100 week MA | $1.36 | 34% above |
| 200 week MA | $1.61 | 13% above |
LXRX's trend is mixed: it's above four of its five weekly moving averages, and 13% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
LXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.26 | $3.49 | -18% |
| 2021 | $3.49 | $4.36 | +25% |
| 2022 | $4.36 | $1.95 | -55% |
| 2023 | $1.95 | $1.53 | -22% |
| 2024 | $1.53 | $0.77 | -50% |
| 2025 | $0.77 | $1.23 | +60% |
| 2026 YTD | $1.23 | $1.82 | +48% |
LXRX has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.